GleamWall
中文EN

FULC Fulcrum Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1680581 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY2,752.0%
TTM net income YoY90.0%
TTM EPS YoY89.9%
Revenue 3-yr CAGR61.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-27.4%
Net margin-12.2%
FCF margin-3.1%
EBITDA margin-25.3%

Returns

ROE-4.1%
ROA-3.8%
ROIC (approx.)-8.8%
Asset turnover0.31x

Leverage & solvency

Liabilities / assets6.8%
Debt / equity0.00x
Current ratio22.63x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.23x
Accruals ratio-2.9%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$0$0$0—$0
R&D expense$3.03M$12.44M$14.08M$15.42M$14.30M$12.99M$13.40M$11.71M
SG&A expense$8.44M$7.46M$8.10M$7.28M$7.56M$6.83M$7.00M$7.72M
Operating income-$13.86M-$29.31M-$22.19M-$22.69M-$21.86M-$19.82M-$20.40M-$19.43M
Net income-$10.94M-$26.18M-$18.89M-$20.33M-$19.59M-$17.30M-$17.66M-$16.57M
EBITDA-$13.56M-$29.11M-$21.85M-$22.35M-$21.56M-$19.52M-$20.05M-$19.06M
EPS (basic)-0.14-0.34-0.25—-0.31-0.28-0.28—
EPS (diluted)-0.14-0.34-0.25—-0.31-0.28-0.28—
Weighted avg. shares (diluted)76.32M76.26M76.22M—62.60M62.54M62.48M—
Balance sheet
Cash & equivalents$116.41M$48.47M$50.26M$197.53M$47.08M$42.59M$42.18M$58.21M
Current assets$310.80M$322.85M$338.67M$357.48M$205.86M$219.37M$232.56M$249.92M
PP&E, net$0$0$2.49M$2.82M$3.17M$3.27M$3.55M$3.90M
Total assets$310.81M$323.95M$346.77M$366.28M$214.86M$228.84M$242.65M$260.72M
Current liabilities$8.59M$10.30M$9.86M$13.05M$11.63M$8.98M$8.10M$11.04M
Total liabilities$8.78M$13.26M$13.47M$17.28M$16.49M$14.46M$14.16M$17.68M
Shareholders' equity$302.03M$310.70M$333.30M$349.00M$198.37M$214.38M$228.49M$243.03M
Shares outstanding76.38M76.29M66.61M66.58M54.11M54.09M53.98M53.97M
Cash flow statement
Operating cash flow-$13.38M-$16.04M-$18.75M-$16.80M-$14.19M-$13.82M-$15.26M-$16.76M
Capital expenditure$0$108,000$8,000$159,000$90,000$65,000$0$231,000
Free cash flow-$13.38M-$16.15M-$18.76M-$16.96M-$14.28M-$13.88M-$15.26M-$16.99M
Investing cash flow$81.13M$13.78M-$128.21M-$1.05M$18.61M$13.93M-$777,000$2.26M
Financing cash flow$198,000$356,000-$312,000$168.30M$64,000$301,000$0$83,000
Depreciation & amortization$300,000$200,000$338,000$347,000$300,000$300,000$353,000$369,000
Stock-based compensation$2.17M$3.27M$3.86M$3.07M$3.36M$2.88M$3.17M$2.48M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.